Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 8 5 PH6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 8 5 PH6.
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN 8.5% (PH6)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
None Documented
None Documented
Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation.
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution